Me-NB1

**Me-NB1** is a small molecule radioligand developed as a PET imaging agent for GluN2B-containing *N*-methyl-D-aspartate (NMDA) receptors, a subtype of glutamate receptors in the central nervous system[2][3][5][6][7]. It is used to quantify and visualize GluN2B receptor distribution and occupancy, particularly relevant in neurological and neurodegenerative disorders such as stroke, Alzheimer’s disease, and Parkinson’s disease[1][3][5][8]. Mechanistically, Me-NB1 binds with high specificity and affinity to the GluN2B subunit of NMDA receptors (K_i: ~4 nM)[1][3], showing high selectivity over sigma-1 receptors[1][3]. Both R- and S-enantiomers have been developed, with the R-enantiomer demonstrating favorable imaging properties and selectivity[1][2][3]. Me-NB1 is primarily utilized as a research tool for PET imaging rather than clinical therapy.

Brand names

Me-NB1Me-NB-1Me-NB 1

Other names

R-[^11C]-Me-NB1S-[^11C]-Me-NB1R-OF-Me-NB1R-OF-Me-NB-1R-OF-Me-NB 1S-OF-Me-NB1S-OF-Me-NB-1S-OF-Me-NB 1